2015 260k 2016 240k 2017 april to sept 643k based on carats sold and av per carat value. If production is maintained at current kevel, that equates to 2 million per year, but it should increase further. So if sp was between 21p and 30p when revenue was only 240k, even with the further diluation that occured, share price looks very low.
should check spelling when using small tablet keys !
If they nanage to keep going with a monthly average as July production and sales, revenue wpuld be 1.5 million a year, however we should expect to see this continue to improve. Watching this with interest as they move furyher into the undiluted kimberlite.
What theory ! All this means is that its a better buy for anyone prepared to wait. Its retail, inflation will drop back, profits will improve again. You seem very keen to talk it even lower, not cheap enough yet ! Its the same type of basely comment i have seen on other shares which have since bounced back. Anyone can spout value trap,, very easy. I look forward to picking up a good share at a even lower price.
Laura ashley have low debt, on line sales are ok, they are a online retailer as well as bricks and morter. Addition revenue from hotels. New offices for asia expansion if i remember correctly, This is now at a buy price , no question, picjed some up earlier today.
Pending in the table of the main report. This just means ongoing, product is on its way (commecial order). And they will do a formal product launch ad we saw last year in Italy and Spain. Within the next month i expect. I will look out for this eith interest. It seemed quite wrll done by sipcam last year.
The statement for sumi agro france, under post period end says, First commercial scale order for France, the word pending does not appear. So maybe someone is reafing a different statement to the one i saw ?
Was this not already expected from the revenue information in December, ! Less revenue, but if you strip out the terpene tech rev, it was actually a increase of revenue from actual sales. A bit premature for the doom and gloom, until we see results from this year under the new sales system and addtional market i would not write them off yet.
2015 eden research financial report, segmented income, milestone and royalties shown against biocides and human health would be the income from terpene tech, not a lot, but its not nothing. I ecpect to see biocides showing sgsin in the 2016 report with small royalty. What is more relavent , the sales this year of 3aey under the new arrangement which will enhance income considerably.
At bottom of report, 28k due to eden, 2015 was 29k, not a lot, but then currently they only have the two pet odour treatments on sale in france, a limited market with a lot of competition. The value if any with terpene tech will be if they get approval of the headlice treatment, but thus will tske a long time, human health related products take a long time. Personally i dont think much of terpene tech, but its a side show at present for eden, success or failure will be on there 3aey and the nematacide, your sell why you can statement is the same old deramp *******s seen so often before with eden. Last time pricre was manipilated downward on inuendo and rumour related to terpene tech, i picked up shares and did very well out of it. Are you trying to make this another chance to pick up cheap shares, considering eden are now in a much stronger position than before ?
Whilst it is easy to find a lot of promotional acyivity by sipcam who really pushed eden, hence the 20% market share in places, i see little evidence from africa of promotional activity. I expect more activity this year in france on the sales and marketing and have started looking out for it.
You can find the product on sumiagro france under fungicides. www.sumiagro.fr/protection/fungicides
Sould check over the text for errors when using the tablet, to easy to miss hit the keys ! I will be happy for now to see a slow increase for africa and eden to concentrate on europe which is a more lucrative market i believe. I will be checking regulary for activity in France this growing season.
The impression i have of edrn is that they will only rns for s first order, after that its trading updates. The december uodate was onky a heafline gigure with no breakdown. I am not ecpecting a big number for kenya, Product was not pushed like it was for spain and italy and next france. As more revenue comes ftom the european 3aey sales, i would expect this to change hopefully and a more concerted educational campaign would be launched as they dud in Italy and spain.
looked into the subject. Warrants are tradeable instruments, which can be bought and sold. Thete is no obligstion for a company to even say who owns them, only the qty outstanding. The qty is shown in the yearly financial report. if theres a story here , its whats going on with oxford capital. As far as eden, its nothing. They have the same number of warrants outstanding now as before. Nothing has materially changed. I picked up some more shares and plan to do so again if funds available at current prices if they persist.
Rather than speculate now, why not wait for the next full year report, last one stated revenue quite clearly. 30k for africa agrochemicals. Quitr simply, they probably do not want to share commecial information of this nature, basic buisness practice.
looked further, and i see company dissolved, and then same name used. The companies web site carries on with news releases straight through including the period between delusting and relisting. Something strange with oxford capital ?
Oxford capital partners who invest in small companies launched a new fund on 3rd of march this year, after they had supposedly ceased to exist. So unless there is another oxford capital, this seems to be a made up story with no substance. try googling oxford capital media eis
I have seen similar rns from many companied prior to agm. itd not unususl to put out a statement regarding voting rights, shares in issue etc.
Yep, they launched new media eis at start of this month, sounds like tw is talking bull shxx again.